HRP20010099A2 - New pharmaceutical uses for nos inhibitors - Google Patents

New pharmaceutical uses for nos inhibitors Download PDF

Info

Publication number
HRP20010099A2
HRP20010099A2 HR20010099A HRP20010099A HRP20010099A2 HR P20010099 A2 HRP20010099 A2 HR P20010099A2 HR 20010099 A HR20010099 A HR 20010099A HR P20010099 A HRP20010099 A HR P20010099A HR P20010099 A2 HRP20010099 A2 HR P20010099A2
Authority
HR
Croatia
Prior art keywords
formula
compound
pyridin
phenyl
ylamine
Prior art date
Application number
HR20010099A
Other languages
English (en)
Croatian (hr)
Inventor
John Adams Lowe Iii
Jolanta Nowakowski
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20010099A2 publication Critical patent/HRP20010099A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010099A 1998-08-11 2001-02-08 New pharmaceutical uses for nos inhibitors HRP20010099A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9615298P 1998-08-11 1998-08-11
PCT/IB1999/001389 WO2000009130A2 (fr) 1998-08-11 1999-08-05 Nouvelles utilisations pharmaceutiques pour les inhibiteurs de nos

Publications (1)

Publication Number Publication Date
HRP20010099A2 true HRP20010099A2 (en) 2002-02-28

Family

ID=22255853

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010099A HRP20010099A2 (en) 1998-08-11 2001-02-08 New pharmaceutical uses for nos inhibitors

Country Status (37)

Country Link
US (1) US20020151572A1 (fr)
EP (1) EP1109556A2 (fr)
JP (1) JP2002522498A (fr)
KR (1) KR20010085364A (fr)
CN (1) CN1323211A (fr)
AP (1) AP2001002067A0 (fr)
AR (1) AR020009A1 (fr)
AU (1) AU749439B2 (fr)
BR (1) BR9912906A (fr)
CA (1) CA2340200A1 (fr)
CO (1) CO5130011A1 (fr)
CR (1) CR6302A (fr)
CZ (1) CZ2001486A3 (fr)
DZ (1) DZ2867A1 (fr)
EA (1) EA200100125A1 (fr)
EE (1) EE200100084A (fr)
GE (1) GEP20043252B (fr)
GT (1) GT199900127A (fr)
HK (1) HK1041819A1 (fr)
HR (1) HRP20010099A2 (fr)
HU (1) HUP0103113A3 (fr)
ID (1) ID28227A (fr)
IL (1) IL141031A0 (fr)
IS (1) IS5814A (fr)
MA (1) MA26670A1 (fr)
NO (1) NO20010685L (fr)
NZ (1) NZ509298A (fr)
OA (1) OA11595A (fr)
PA (1) PA8479801A1 (fr)
PE (1) PE20001025A1 (fr)
PL (1) PL346842A1 (fr)
SK (1) SK1702001A3 (fr)
SV (1) SV1999000121A (fr)
TN (1) TNSN99154A1 (fr)
TR (3) TR200100434T2 (fr)
WO (1) WO2000009130A2 (fr)
YU (1) YU9601A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
US6586478B2 (en) 2000-02-22 2003-07-01 Cellegy Canada Methods and compositions for improving sleep
EP1495026A4 (fr) * 2002-03-20 2008-07-09 Univ Queensland Procedes et compositions contenant des donneurs d'oxyde nitrique et des analgesiques opioides
WO2005007627A1 (fr) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif
US9120750B2 (en) 2013-03-07 2015-09-01 Northwestern University 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors
US9951014B2 (en) 2014-11-04 2018-04-24 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002270B1 (ru) * 1996-03-29 2002-02-28 Пфайзер Инк. Производные 6-фенилпиридил-2-амина
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
CA2277990C (fr) * 1997-02-10 2006-08-01 Pfizer Products Inc. Pyridines a substitution 2-amino-6-(2-substitue-4-phenoxy)
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination

Also Published As

Publication number Publication date
NO20010685L (no) 2001-04-09
WO2000009130A2 (fr) 2000-02-24
CR6302A (es) 2004-03-24
GEP20043252B (en) 2004-06-25
OA11595A (en) 2004-08-19
IL141031A0 (en) 2002-02-10
BR9912906A (pt) 2001-05-08
TR200103661T2 (tr) 2002-06-21
JP2002522498A (ja) 2002-07-23
PL346842A1 (en) 2002-02-25
CZ2001486A3 (cs) 2002-06-12
CO5130011A1 (es) 2002-02-27
AR020009A1 (es) 2002-03-27
CA2340200A1 (fr) 2000-02-24
TR200100434T2 (tr) 2001-07-23
TR200401803T2 (tr) 2004-11-22
HK1041819A1 (zh) 2002-07-26
EP1109556A2 (fr) 2001-06-27
SV1999000121A (es) 2000-07-06
WO2000009130A3 (fr) 2000-05-18
AU749439B2 (en) 2002-06-27
CN1323211A (zh) 2001-11-21
TNSN99154A1 (fr) 2005-11-10
HUP0103113A3 (en) 2002-02-28
SK1702001A3 (en) 2003-02-04
AP2001002067A0 (en) 2001-03-31
HUP0103113A2 (hu) 2002-01-28
US20020151572A1 (en) 2002-10-17
GT199900127A (es) 2001-01-30
YU9601A (sh) 2003-12-31
NO20010685D0 (no) 2001-02-09
KR20010085364A (ko) 2001-09-07
ID28227A (id) 2001-05-10
EE200100084A (xx) 2002-08-15
DZ2867A1 (fr) 2003-12-15
PA8479801A1 (es) 2000-09-29
AU4924899A (en) 2000-03-06
EA200100125A1 (ru) 2001-08-27
MA26670A1 (fr) 2004-12-20
PE20001025A1 (es) 2000-10-11
IS5814A (is) 2001-01-16
NZ509298A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
JP3411271B2 (ja) Nos阻害剤であり縮合環置換基を含む2−アミノピリジン類
CA2915561C (fr) Nouveaux composes bicycliques substitues utilises comme inhibiteurs de bromodomaines
JP6005050B2 (ja) 複素環式アミンおよびその使用
EP1471055A1 (fr) Dérivés de 6-phenylpyridyl-2-amines
CA2670165A1 (fr) Derives de 2-[(2-substitues)-indolizine-3-yl]-2-oxo-acetamide et leur utilisation comme agents antifongiques
EP2539336B1 (fr) Hétarylaminonaphtyridines
US20070049620A1 (en) Cyclic tertiary amine compound
CA3190653A1 (fr) Inhibiteurs de bromodomaine bicycliques
HRP970664A2 (en) 6-phenylpyridyl-2-amine derivatives
US7902219B2 (en) 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof
KR20140027366A (ko) Nampt의 억제를 위한 신규 화합물 및 조성물
AU2008240790A1 (en) Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
CA3007168A1 (fr) Inhibiteurs heterocycliques 1h-imidazo[4,5-b]pyridinyle et 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyle de proteine a bromodomaines bet
AU2935300A (en) New pharmaceutical combinations for nos inhibitors
HRP980476A2 (en) Branched alkoxy-substituted 2-aminopyridines
AU2011261164A1 (en) Haematopoietic-prostaglandin D2 synthase inhibitors
HRP20010099A2 (en) New pharmaceutical uses for nos inhibitors
KR101803866B1 (ko) 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
US20040229911A1 (en) New pharmaceutical combinations for NOS inhibitors
JP2024516429A (ja) メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用
AU3438799A (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
MXPA01001548A (en) New pharmaceutical uses for nos inhibitors
US20010049379A1 (en) 2-aminopyridines containing fused ring substituents

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040616

Year of fee payment: 6

OBST Application withdrawn